Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced that it has moved its R&D operations to the Campus Biotech, a new life sciences center of excellence located at the former Merck Serono site in Geneva.
Campus Biotech creates new opportunities for scientists and entrepreneurs by providing a unique environment to translate ideas into products that will impact society and the world. Extending out over 40,000m2, this unique center of excellence in Europe welcomes many academic and industrial partners, of which, in particular, teams from EPFL (the Lausanne-based Swiss Federal Institute of Technology), UNIGE (University of Geneva), the University Hospitals of Geneva, the Wyss Centre of bio- and neuro-engineering, the Human Brain Project, the Swiss Institute of bioinformatics, and the HEPIA which is part of the HES-SO (University of Applied Sciences Western Switzerland).
This new ecosystem is based on an interdisciplinary scientific approach to stimulating innovation in the area of life sciences. Its main objective is to concentrate on pure science and its transposition into products which will have a direct impact on society and on the world. Campus Biotech acts as a catalyst of a new surge and new investments in the essential sector of economics and science, and was established by a consortium made up of the EPFL, UNIGE, the Bertarelli family and HansJörg Wyss.
"We are delighted to welcome Addex to our center of excellence in life science. As a leader in allosteric modulator drug discovery which is ideally suited to neuroscience, Addex is perfectly aligned with our mission to build a center of excellence in life science and in particular neuroscience," commented Dr. Benoît Dubuis, director Campus Biotech and development director Wyss Center.
"Joining the center of excellence in life science and in particular neuroscience that is being created at the Campus Biotech will provide Addex with access to multiple cutting edge scientific platforms," commented Tim Dyer CEO at Addex. "We believe being part of the Campus's blend of science and industry, is the perfect environment for Addex to excel as we execute on our strategy to advance our portfolio of allosteric modulator drug candidates."